Study summary · research use only
Thymosin alpha-1 treatment in chronic hepatitis B
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This editorial reviews studies on thymosin alpha-1 (Talpha-1), an immunomodulatory agent, in chronic hepatitis B (CHB). The abstract states Talpha-1 can enhance T-cell response in CHB patients and has been studied alone or with nucleos(t)ide analogs, drawing on English and Chinese articles from MEDLINE, EMBASE, the Cochrane Controlled Trial Registry and Chinese databases. It reports that Talpha-1 monotherapy was associated with suppressed viral replication compared with untreated controls or conventional interferon, that most combinations of Talpha-1 with lamivudine or IFN-alpha showed greater effects on HBV DNA suppression and HBeAg seroconversion, and that studies of Talpha-1 with entecavir in HBV-cirrhosis are ongoing.
Abstract
Stimulating a successful host immune response may be a promising helpful therapy to achieve elimination of hepatitis B virus (HBV) infection in chronic hepatitis B (CHB). Thymosin α-1 (Tα-1), as an immunomodulatory agent, can enhance T-cell response in CHB patients and has been widely studied either alone or in combination with nucleos(t)ide analogs. This editorial reviews these articles to present the efficacy of Tα-1 in CHB. English and Chinese articles in MEDLINE, EMBASE, the Cochrane Controlled Trial Registry, Chinese periodical full-text database of science and technology, Chinese periodical full-text database and Wan-fang database by thesis search were collected and reviewed. In CHB, Tα-1monotherapy is effective in suppressing viral replication compared with untreated control or conventional interferon. Most of the combination therapy of Tα-1 plus either lamivudine or IFN-α showed better effects on HBV DNA suppression and HBeAg seroconversion. Presently, clinical studies of Tα-1 combined with entecavir on the treatment of HBV-cirrhosis are ongoing.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.